Merck has received FDA approval for a new combination HIV treatment, providing patients with an alternative option to a well-established pill from Gilead Sciences that has faced tolerance and serious side effect issues. The newly approved medication, branded as Idvynso, is specifically indicated for adults who have achieved very low levels of the virus in their blood through the use of antiretroviral drugs. Merck announced that Idvynso will be available at pharmacies starting May 11.<\/p>\n
Idvynso contains doravirine, an already approved drug that Merck markets under the name Pifeltro when used in combination with other antiretroviral agents, and as Delstrigo for standalone treatment. Doravirine functions as a non-nucleoside reverse transcriptase inhibitor (NNRTI), blocking a critical enzyme necessary for HIV replication. In Idvynso, doravirine is combined with islatravir, a new molecule that acts as a nucleoside reverse transcriptase inhibitor (NRTI) and employs multiple mechanisms to inhibit viral replication.<\/p>\n
Gilead’s top HIV treatment, Biktarvy, combines three drugs in a single daily pill. The company projected sales of $14.3 billion for Biktarvy in 2025, representing a 7% increase from the previous year. However, Biktarvy is associated with significant risks, including reports of elevated blood lactate levels and severe liver complications, some of which have been fatal. In contrast, no similar issues were noted during clinical trials of Idvynso.<\/p>\n
Merck’s submission for Idvynso was supported by two Phase 3 clinical trials, both demonstrating that the new medication was not inferior to an active comparator, which included Biktarvy in one instance. Results indicated that patients transitioning from Biktarvy to Idvynso experienced similar outcomes.<\/p>\n
In 2021, the FDA partially paused clinical testing of Merck\u2019s HIV medication due to concerns about lower levels of immune cells in treated patients; this pause was lifted later, allowing Merck to resume trials with a lower dosage. According to Merck, the average levels of immune cells were consistent across treatment groups, and no treatment interruptions occurred due to reduced immune cell levels. Additionally, any weight changes post-treatment with Idvynso were found to be modest.<\/p>\n
A recent report from GlobalData indicated a market shift away from single-tablet HIV regimens containing three or more medications, favoring simpler two-drug combinations that minimize toxicity. This trend positions Idvynso as a potential competitor to GSK’s Dovato, which combines dolutegravir and lamivudine.<\/p>\n
Clinicians interviewed by GlobalData emphasized that Idvynso must demonstrate a reduced incidence of side effects relative to standard therapies like Biktarvy, particularly regarding weight gain and central nervous system tolerability. The firm estimated that Merck’s new HIV treatment could generate sales of approximately $1.8 billion by 2033 in the U.S., France, Germany, Italy, Spain, the UK, and Japan.<\/p>\n
“As the existing treated populations age, there will be escalating demand for metabolically neutral and easily tolerable regimens, creating targeted but significant market expansion opportunities,” noted Anaelle Tannen, an infectious disease analyst at GlobalData.<\/p>\n
If Idvynso achieves GlobalData’s sales projections, it could become Merck’s best-selling product in its currently limited virology portfolio. There is potential for the label to expand to treatment-na\u00efve HIV patients as Merck is evaluating the drug combination in pivotal trials involving individuals who have never received antiretroviral therapy. Recent results from Phase 3 trials indicated that the investigational drug met its primary endpoint of demonstrating non-inferiority to Biktarvy, findings which were presented at the Conference on Retroviruses and Opportunistic Infections and subsequently published in The Lancet HIV.<\/p>\n
Image credit: Flickr user NIAID<\/a> via Creative Commons license<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Merck has received FDA approval for a new combination HIV treatment, providing patients with an…<\/p>\n","protected":false},"author":1,"featured_media":1410,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[19],"tags":[],"class_list":["post-1409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma"],"_links":{"self":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/comments?post=1409"}],"version-history":[{"count":1,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1409\/revisions"}],"predecessor-version":[{"id":1411,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1409\/revisions\/1411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media\/1410"}],"wp:attachment":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media?parent=1409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/categories?post=1409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/tags?post=1409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}